BACKGROUND
After decades of virtually no progress, multiple myeloma survival has improved significantly in the last 10 years, in younger patients even 2-3 fold. (1) (2) (3) In fact, multiple myeloma has seen more remarkable progress in treatment and patient outcomes than any other cancer in the last decade. With improvements in survival, a relatively new clinical challenge which has emerged is the risk of second malignancies. This pattern of increase in second malignancies has been observed in other cancers with available curative therapies and favorable outcomes. Survivors of testicular cancer are at up to 3-fold higher risk of developing a second malignancy than the general population.(4) Survivors of Hodgkin lymphoma have more than three times greater risk of solid tumors. Fifteen years after diagnosis, the cumulative mortality from second malignancies exceeds cumulative mortality from Hodgkin lymphoma. (5, 6) In the U.S. alone, the number of cancer survivors has tripled since 1971 and is growing by 2% each year; cancer survivors constitute 3.5% of the U.S. population. (7) In fact, second-or higher-order cancers account for 18% of incident cancers in the U.S. making them the third most common cancer diagnosis.(7) Based on the NCI SEER (Surveillance, Epidemiology and End Results) database, compared to the general population, cancer survivors have a 14% increased risk of developing a malignancy. (7) In the late 1960s, based on a restricted number of patients, an association between multiple myeloma and leukemia was first reported. (8) (9) (10) In 1979, based on a clinical trial including 364 multiple myeloma patients, Bergsagel et al reported a greater than expected incidence of all forms of acute leukemia for patients treated with low-dose melphalan containing combinations of alkylating agents. (11) In the era where low-dose melphalan was the mainstay of multiple myeloma therapy, due to poor overall survival rates, the absolute number of multiple myeloma patients at risk for acute leukemia was small. Although use of low-dose melphalan declined substantially with the advent of high-dose melphalan followed by autologous stem cell transplantation (ASCT) in the late 1980s, melphalan-based combinations continue to be used in ASCT-ineligible patients. (12) In the post-transplant era, several studies found that conventional chemotherapy preceding the transplant played a greater role in the development of myelodysplastic syndromes (MDS) and acute leukemia than myeloablative therapy used in conjunction with ASCT. In the last decade, agents with new mechanisms of action (such as, thalidomide, bortezomib and lenalidomide) and continuing improvements in supportive care
have further improved response rates, progression free survival and overall survival in multiple myeloma. Recent preliminary reports of increased risk of second malignancies, predominantly MDS/acute leukemia, with lenalidomide have further highlighted this challenge in multiple myeloma patients. Increased risks were also noted for Kaposi's sarcoma and chronic myeloid leukemia. (7) However, the overall risk of developing any type of a subsequent primary cancer was not increased. The increased risk of developing a new malignancy was limited to individuals diagnosed with multiple myeloma at ages younger than 70 years; subsequent cancer risk did not differ by gender, race, or initial therapy. It is to be noted that NCI SEER database did not capture Overall, based on a restricted number of investigations, most prior studies implicate treatment-related factors as the main contributing factor to development of second malignancies following multiple myeloma. However, the lack of molecular markers that are specific for therapy-induced cancer and inability to compare different treatment durations in a clinical trial setting limits our ability to define the impact of prior therapy in the etiology of a second malignancy. In fact, it seems reasonable to propose that second malignancies in multiple myeloma may not be attributable solely to prior treatment. Rather, the development of second malignancies may reflect combinations of influences including treatment-related, multiple myeloma-related, host-related, environmental and behavioral factors ( Figure 1 ).(17) In this paper, we review and discuss our current understanding of second malignancies following multiple myeloma.
TREATMENT-RELATED FACTORS
The effects of treatment-related factors, including oral alkylating therapy on the development of malignancies following multiple myeloma have been assessed (Table 1) . (11, 13, 14, 18-22) Bergsagel et al conducted the first prospective clinical study evaluating the value of a combination of three alkylating agents in the treatment of multiple myeloma: melphalan, cyclophosphamide and carmustine. In their study, the observed vs. expected incidence of all forms of acute leukemia was increased for all age groups. (11) In fact, the patterns are quite similar to investigations focusing on Hodgkin lymphoma24 and non-Hodgkin lymphoma (23) showing MDS/acute leukemia to be associated with long-term alkylating therapy, and with a cumulative dose-response effect. Since these early observations, treatment-related factors including melphalan have been considered the main cause of excess of MDS/acute leukemia in multiple myeloma patients, although the biological mechanisms were not well defined. In a subsequent study, Cuzick et al. reported a positive association between the duration of melphalan treatment and the subsequent risk of developing leukemias. (22) In that study, the cumulative dose melphalan given up to three year period prior to leukemia diagnosis was reported to be the most important determinant of risk. However, this association has not held true in all studies. For example, a retrospective cohort study from the Finnish Leukemia Group found no significant association between the duration and cumulative doses of melphalan and AML risk subsequent to multiple myeloma.(13) Also, in another study, cyclophosphamide was found to be less Taken together, mostly based on small numbers, prior studies have found various types of therapies (such as, oral alkylating therapy, myeloablative therapy used in conjunction with ASCT, radiotherapy and lenalidomide) to be associated an excess of second malignancies following multiple myeloma. Yet the exact underlying mechanisms remain to be determined and several studies to elucidate the underlying mechanisms are ongoing.
MULTIPLE MYELOMA-RELATED FACTORS
Although presenting with the same histologic picture, multiple myeloma displays a broad molecular range characterized by subgroups with unique gene expression profiles, which correlate with clinical characteristics and patient survival. Moreover, additional molecular events including epigenetic changes and activation of molecular pathways occur during multiple myeloma progression and treatment. (36, 37) In a recent population-based study from Sweden, based on 5652 patients with multiple myeloma precursor disease, monoclonal gammopathy of uncertain significance (MGUS), an 8-fold increased risk of developing MDS/AML was observed. (15) The elevated risk was confined to those with IgG/IgA (and not IgM) MGUS. Interestingly, MGUS patients with M-protein concentrations >1.5 g/dL (SIR=11.12) had higher risk than those with ≤1.5g/dL (SIR=4. 67) suggesting that more active precursor disease has similar baseline risk for AML/MDS to that of active multiple myeloma. (15) Overall, these observations are important in that they support a role for disease related factors in MDS/AML following multiple myeloma and raises the question whether underlying molecular heterogeneities in multiple myeloma may be related to the risk of developing second malignancies. It is possible that certain molecular multiple myeloma subgroups are at a higher risk than others. For example, a potential mechanism could be selective pressure (i.e., a pre-existing non-dominant clone, unresponsive to treatment) leading to an increased susceptibility to developing second malignancies. A better understanding of underlying molecular mechanisms across multiple myeloma subgroups and risk of second malignancy will form the basis for modification and targeting therapies to specific subgroups, with the overall goal to minimize the risk of second malignancies.
HOST-RELATED FACTORS
Although we lack large well-designed studies at this time, based on work done on other cancer types, it seems reasonable to propose that host-related (including both genetic and non- prolonged in all three studies of lenalidomide maintenance and in one of these, the CALGB 100104 trial of lenalidomide maintenance after high-dose melphalan/ASCT there was also a significant overall survival benefit. In summary, these facts are tightly intertwined and there are multiple aspects to consider. Although there are few clear answers available at this time, in our opinion, clinicians need to discuss the risks and benefits with patients and stay updated as more data becomes available. Until we have access to better knowledge, in our opinion, in circumstances where the benefit of maintenance therapy in terms of overall survival is not well established, the risks versus any possible benefit should be taken more cautiously.
FUTURE DIRECTIONS
In the context of increasing overall survival in multiple myeloma, and the recently reported increase of second malignancies associated with use of lenalidomide (30) (31) (32) , it is imperative that we re-address the association between multiple myeloma and leukemia which was first reported in the late 1960s. 
